Trial Profile
Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pegfilgrastim (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Neutropenia; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Oct 2020 Results published in the Supportive Care in Cancer
- 06 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2017 Status changed from not yet recruiting to recruiting.